From a modest CSIR lab to a 7000 m² state-of-the-art facility, Design Biologix has become a beacon of innovation in animal health. Specialising in Southern African livestock and wildlife vaccines, the company combines rigorous research, rapid response autogenous vaccines, and international-quality manufacturing standards. Their animal-centric approach empowers veterinarians and farmers alike, safeguarding animal health from snout to tail.

The catastrophic outbreak of foot-and-mouth disease in South Africa highlights the important role that vaccines play in animal health. In this challenging landscape, Design Biologix stands as a beacon of innovation and resilience. Founded in 1994 by three dedicated professionals — Pieter Smuts (veterinary microbiologist), George Gaenssler (veterinarian and pharmacologist), and Karen Nel (biochemist) — the company began with a simple yet powerful vision: To set a standard in animal healthcare solutions, prioritising innovation with compassion.

“We started the operations of the company in one tiny lab at the Council for Scientific and Industrial Research (CSIR) in Pretoria, with the oldest, most affordable equipment that could do the job,” recalls Karen, now the independent owner and driving force behind Design Biologix following the tragic COVID-related death of co-founder Pieter Smuts in 2021.

What began as a modest operation manufacturing a single intra-dermally administered pasteurellosis vaccine called Pastvac has evolved into a leading vaccine developer with expanded facilities and significantly increased annual vaccine output.

The growth journey: From humble beginnings to industry leadership

The company’s growth trajectory reflects both strategic vision and organic development. Initially operating from a single laboratory at the CSIR, Design Biologix gradually expanded to occupy ~1000 square meters of area, including laboratories and offices. However, by 2018-2019, space constraints necessitated a major transition.

“We were running out of space and started looking for our own building,” Karen explains. The search for suitable premises took ~18-months, ultimately culminating in the acquisition of their current state-of-the-art facility spanning 7000 square meters, complemented by an additional 1000 square meters of warehouse space.

In 2026, Design Biologix moved into their new premises in Erasmuskloof, Pretoria. The company currently employs 95 people and operates with an impressive annual production capacity of 90 million vaccine doses, selling ~40 million doses annually to veterinarians, feedlots, and farmers across Southern African Development Community countries.

Becoming fully integrated: A strategic transformation

A pivotal moment in Design Biologix’s evolution occurred when the company made a strategic decision to become fully integrated. “We decided that we were not going to be developing products for other companies anymore. We would do all the research, register the products ourselves, manufacture ourselves, do the distribution ourselves, do the marketing ourselves,” Karen explains.

This transformation represented a significant shift from their previous business model, requiring new capabilities in registration and expanded marketing efforts. The decision to maintain complete control over their value chain — from research and development through to market delivery — exemplifies their commitment to quality and their animal-centric philosophy of supporting veterinarians and farmers with innovative solutions ‘from snout to tail’.

Research and development excellence

At the heart of Design Biologix’s success lies a robust research and development (R&D) programme led by a team of four PhDs and three laboratory assistants. This dedicated R&D team focuses on three primary areas: Improving existing products, developing new vaccines, and responding to field feedback about emerging disease outbreaks.

The company’s approach to vaccine development reflects deep understanding of local conditions and needs. Karen explains their success rate: “If we develop 100 vaccines, probably ~80 would be successful” — a remarkably high success rate that speaks to their scientific rigour and market understanding.

However, she qualifies this by noting that it is not to say they are going to work 100%, but as a rough guess, she thinks they have only produced one or two that have not gone through to a final product.

Specialisation in Southern African challenges

Design Biologix’s primary focus centres on diseases unique to Southern Africa, with their passion lying in ‘the prevention and control of animal diseases that are unique to Southern Africa’. This geographical specialisation has proven both strategically sound and practically valuable, as prevention of disease spread to other continents has significantly broadened their market reach.

Currently, their biggest-selling product is a multi-clostridial vaccine for cattle that includes anthrax protection. Their second-largest seller addresses bovine ephemeral fever.

The company’s expertise extends beyond traditional livestock to encompass wildlife species including rhinoceros, sable, lion, cheetah, and wild dog — a specialisation that reflects their commitment to South Africa’s unique conservation challenges and opportunities.

Autogenous vaccines: Custom solutions for unique challenges

One of Design Biologix’s key differentiators lies in their specialisation in autogenous vaccines — custom-prepared emergency vaccines consisting of herd-specific antigens formulated as inactivated final products.

“Autogenous vaccines are vaccines that are made specifically for a farm or the farms around it where something breaks out that there isn’t an existing vaccine for, or the existing vaccine doesn’t work,” Karen explains.

This capability addresses a critical gap in animal health management, providing rapid response solutions when standard vaccines prove inadequate or when new disease challenges emerge. The company’s R&D team maintains constant communication with field veterinarians who alert them to emerging threats, enabling quick response to novel disease challenges.

Regulatory framework and quality assurance

Design Biologix operates under Act 36 of 1947, with veterinary vaccines classified as stock remedies under the Farm Feeds, Fertilisers and Stock Remedies Act. This regulatory framework, distinct from South African Health Products Regulatory Authority oversight of veterinary medicines, allows the company to maintain their specialised focus while ensuring compliance with appropriate quality and safety standards.

The company’s manufacturing processes adhere to European Pharmacopoeia standards, ensuring that their products meet international quality benchmarks despite their focus on local and regional markets. This commitment to quality extends throughout their operations, from their state-of-the-art cold chain management — critical for vaccine efficacy — to their rigorous testing and validation processes.

Addressing industry challenges and opportunities

Karen’s perspective on vaccination challenges reveals important insights into animal health dynamics in South Africa. She notes that while commercial farmers generally vaccinate their livestock, companion animal vaccination remains limited. “The average lifespan of a dog in South Africa is two years,” she observes, highlighting the broader animal health challenges facing the country.

She emphasises that vaccine hesitancy in animals differs from human vaccine hesitancy, as it is often driven more by financial constraints than concerns about side effects. She notes that human vaccines are frequently government-funded, whereas animal vaccines are typically paid for by owners. This economic reality shapes Design Biologix’s approach to product development and pricing strategies.

Future directions and advanced diagnostics

Looking forward, Design Biologix plans to expand into advanced diagnostics, conducting what Karen terms ‘post-pathologist’ analysis. We would like to do advanced diagnostics, she explains, citing serotyping for bluetongue as an example. This capability would enable the company to improve existing vaccines by identifying emerging strains and incorporating them into their formulations.

This planned expansion into advanced diagnostics represents natural evolution for a company committed to comprehensive animal health solutions, requiring additional accreditation but leveraging existing equipment and expertise.

Legacy and impact

Since 1994, Design Biologix has proudly served the commercial animal market, developing superior quality vaccines with unwavering commitment to advancing animal health. Their journey from a small CSIR laboratory to a leading regional vaccine manufacturer exemplifies the potential for locally-focused innovation to address specific regional challenges while maintaining international quality standards.

Today, as an independently owned company under Karen’s leadership, Design Biologix continues to embody their founding vision: Empowering the animal health industry with scientific advancements and world-class manufacturing, maintaining their animal-centric approach that supports veterinarians and farmers with innovative solutions from ‘snout to tail’.

In a world where animal health challenges continue to evolve, Design Biologix stands ready to meet tomorrow’s challenges with the same dedication, innovation, and compassion that have defined their journey for more than three decades.